Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies. - Panse J; Han B; Cermak J; Gonzalez Fernandez FA; Gotoh A; Kulasekararaj AG; Kyselova O; Sahin F; Scheinberg P; Schrezenmeier H; Straetmans N; Ueda Y; et al. (Annals of hematology, 2025)